A novel type of cancer biomarker: detection of the inactive amyloid protein state of p16
Problem:
A new type of anti-cancer drug called CDK-inhibitors has become available and is funded in New Zealand for certain breast cancer patients. These drugs are powerful, but only one-third of patients actually respond to them. Right now, there is no way to know which patients will benefit from this treatment.
Project:
We found that a protein called p16, which CDK-inhibitors replace, can turn into an inactive form similar to structures seen in some brain diseases. Current medical tests can't tell the difference between the active and inactive forms of p16. In this project, we will test breast cancer samples for the inactive form of p16 to see if it potentially predicts treatment success.
Outcome:
If we can reliably identify this inactive form of p16, it could help us predict which patients will respond well to CDK-inhibitors, allowing for more effective treatment.
Future:
This work could lead to a simple test to determine if patients will benefit from CDK-inhibitors and could eventually help expand the use of these drugs for other types of cancer.
Keep reading
View all
From Evidence to Action: Expanding the ‘Not a One-Size-Fits-All’ Breast Cancer Screening Model for Aotearoa New Zealand.
Problem:Breast cancer screening in Aotearoa New Zealand does not benefit all women equally. Many cancers are still found outside the national screening programme, and Māori and Pacific women can fa...
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Problem:Traditional pathology uses microscopes to examine tissue slides, but this method can be slow and inconsistent, and not all patients can afford advanced molecular testing. Project:Digital pa...
“Shielding” Macrophages: Uncovering Immune-Mediated Chemoresistance in Triple-Negative Breast Cancer
ProblemTriple-negative breast cancer (TNBC) is one of the hardest types to treat and affects Māori and Pacific women more than others. Many patients with TNBC don’t fully respond to chemotherapy, a...
